Here is my preliminary analysis:
I am now much more confident that Acrow will achieve another year of high growth. However, as I try to be conservative with my estimates, I will assume for the calculations below that the EPS growth rate is only 25% in FY25, compared with CAGR of > 50% over the last 3 years (see my earlier post on 25 August: Post #: 75362590).
Based on this assumption, EPS for FY25 would be approx. 12.4 cents (using my own normalisation that I explained in that earlier post). At a share price of $1.10, that equates to a FY25 P/E of 8.9.
As I have also previously stated, it is inconceivable to me that Acrow is on a sub-10 forward P/E given the very high levels of profitability and growth rates over the last four years. IMO, it is a growth stock valued as if it had no growth.
If the market was to give Acrow a more realistic but still conservative P/E of, say, 12, then that would mean a share price of $1.49.
If this pans out, then the share price would be 35% higher than now.
- Forums
- ASX - By Stock
- Ann: Expanded Debt Funding & Record Quarterly New Hire Contracts
ACF
acrow limited
Add to My Watchlist
1.01%
!
$1.00

Here is my preliminary analysis:I am now much more confident...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$1.00 |
Change
0.010(1.01%) |
Mkt cap ! $304.8M |
Open | High | Low | Value | Volume |
99.0¢ | $1.00 | 99.0¢ | $109.7K | 110.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 17696 | 99.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.01 | 26427 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 10278 | 0.985 |
1 | 15000 | 0.980 |
2 | 13715 | 0.975 |
6 | 40945 | 0.970 |
9 | 76038 | 0.965 |
Price($) | Vol. | No. |
---|---|---|
0.990 | 50705 | 2 |
0.995 | 10000 | 1 |
1.000 | 9740 | 1 |
1.005 | 1715 | 1 |
1.010 | 12642 | 3 |
Last trade - 10.08am 04/07/2025 (20 minute delay) ? |
Featured News
ACF (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
Previous Video
Next Video
SPONSORED BY The Market Online